Increasing Colorectal Cancer Screening Uptake With a Patient Navigator
NCT ID: NCT01506687
Last Updated: 2013-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
750 participants
INTERVENTIONAL
2010-01-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A majority of patients will opt for Fecal Occult Blood Testing (FOBT)as one of their preferred tests, after undergoing the "Patient Navigator" intervention and that proportion will be significantly greater than the group who opt for FOBT in the control group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patients Navigator for Organized Colorectal Cancer Screening
NCT02369757
Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population
NCT01385579
Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants
NCT00617071
Increasing Uptake of Colorectal Cancer Screening in Ontario
NCT01629004
Study of Patient Navigation to Promote Colon Cancer Screening
NCT01141114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Number of patients who receive a letter and patient navigation services and get screened compared to the control group.
Secondary Outcome Measures:
Proportion (%) of patients preferring FOBT vs.colonoscopy; Predictors of CRC screening and screening preference.
Subjects: Ambulatory patients (men-women aged 50 years and above) recruited from primary care practices at the Group Health Centre, Sault Ste Marie, Ontario. All patients will be screened for eligibility and those who are eligible and agree to participate in the study will be randomized to either of the two study arms: intervention group or control group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Navigator intervention
Health counselling by nurse navigator
Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
Usual Care Control
Usual care
Usual primary care counselling
Usual care health counselling on colorectal cancer and screening options
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Health counselling by nurse navigator
Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
Usual primary care counselling
Usual care health counselling on colorectal cancer and screening options
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Unscreened - Defined as no prior CRC screening
* Under-screened - Defined as no FOBT screening within the last two years
* No colonoscopy or barium enema screening within the last five years
* Willing to provide consent to participate in the study.
Exclusion Criteria
* colonoscopy within five years
* barium enema within five years
* flexible sigmoidoscopy within five years
* Bowel cancer.
50 Years
74 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Cancer Care Ontario
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul Ritvo, Ph.D.
Scientist, Research, Prevention and Cancer Control
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Ritvo, PHD
Role: PRINCIPAL_INVESTIGATOR
Cancer Care Ontario
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Group Health Centre
Sault Ste. Marie, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-163
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.